510(k) device
Eclipse Treatment Planning System (18.1)
Varian Medical Systems · System, Planning, Radiation Therapy Treatment (MUJ, Class II) · First FDA decision Jul 26, 2004, newest Dec 11, 2024Cancer radiation therapy
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
15
510(k) pathway
Device trials
27
Naming "Eclipse"
MAUDE reports
0
Brand "Eclipse", since 2015
PubMed studies
4,515
Mentioning "Eclipse"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eclipse Treatment Planning System (18.1)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 15 decisions filed under this name.
FDA's records could not be loaded.
Older decisions: K170969, K152393, K141283, K133247, K131891, K102011, K073020, K050296, K041403
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40168Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40179CGS Administrators, LLCUpdated Apr 17, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40193WPS Insurance CorporationUpdated Mar 12, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40189Palmetto GBAUpdated Mar 11, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40176Noridian Healthcare Solutions, LLCUpdated Mar 10, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Hyperbaric Oxygen Therapy for Chronic Radiation Induced Proctitis and EnteritisNational analysisReview closedCAG-00060R2Updated Nov 18, 2026
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Eclipse", any status and sponsor, newest update first.
Eclipse Regenesis, Inc.Academic, hospital or other
NCT05535361 · 40 participants (planned) · Start Sep 15, 2023 · Primary completion Mar 1, 2028
Device: Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome · For: Short Bowel Syndrome
Sites: Palo Alto, California; San Francisco, California; Washington D.C., District of Columbia · 5 sites in all
26 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eclipse", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MUJ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Eclipse"[tiab]. The summary above synthesizes these.
- [Eclipse of science].
Fischer A · Med Sci (Paris) · 2025Editorial
- Eclipse retinopathy.
Michaelides M, Rajendram R, Marshall J, et al. · Eye (Lond) · 2001
- Soemmering Ring Eclipse.
Asanad S, Ma EL, Alexander JL · Am J Ophthalmol · 2021
- Eclipse retinopathy.
Dhir SP, Gupta A, Jain IS · Br J Ophthalmol · 1981
- [Eclipse retinopathy].
Johannessen S, Høgsbro M · Ugeskr Laeger · 2014Case Reports
- Solar Eclipse Maculopathy.
Vora RA, Dossetor FM, Lowe RJ · Ophthalmol Retina · 2018Case Reports
- SOLAR ECLIPSE PROBLEMS.
Moore JH · Science · 1933
- Safely Viewing a Solar Eclipse.
Bressler NM · JAMA Ophthalmol · 2024Comment
- Eclipse retinopathy.
Lloyd DF · P N G Med J · 1983
- ECLIPSE BLINDNESS.
Lodge WO · Br Med J · 1921
- Solar eclipse safety.
Mainster MA · Ophthalmology · 1998Editorial, Review
- Pacific Eclipse: Before the corona dawn.
Kelleher AD · Vaccine · 2022Editorial
Other devices of this type
Also filed under product code MUJ.
- syngo.via RT Image SuiteSiemens Medical Solutions USA, Inc. · 510(k) 2024
- RayStation (2024A SP3)RaySearch Laboratories AB (PUBL) · 510(k) 2025
- RT Elements (4.5)Brainlab AG · 510(k) 2025
- Monaco RTP System (6.3)Elekta Solutions AB · 510(k) 2026
- Corvus Radiation Therapy Planning SystemBest Nomos · 510(k) 2021
- Cyberknife Robotic Radiosurgery SystemAccuray, Inc. · 510(k) 2006
- ClearCalc Model RADCA V2.6Radformation, Inc. · 510(k) 2025
- OncospaceOncospace, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.